Incyte completes acquisition of Vega Therapeutics for $1.25B upfront payment

Incyte Corporation has completed its previously announced acquisition of Vega Therapeutics, Inc., a subsidiary of Star Therapeutics, to expand its hematology portfolio. The acquisition adds a late-stage asset, VGA039, a novel monoclonal antibody being developed for the treatment of von Willebrand disease (VWD).

Key Details

• Financial Terms: Incyte acquired all outstanding shares of Vega Therapeutics for $1.25 billion upfront. Star Therapeutics is eligible for up to an additional $750 million in sales-based milestone payments.
• Acquired Asset: The primary asset is VGA039, an investigational monoclonal antibody in Phase 3 development for VWD. It has the potential to be the first once-monthly subcutaneous prophylactic therapy for the disorder.
• Strategic Impact: The acquisition strengthens Incyte's late-stage pipeline and expands its presence into the bleeding disorders market. The transaction will be recorded as a one-time R&D expense in Q3 2026.